Wednesday, January 02, 2008 2:27:42 PM
One of my top picks going into 2008 is RBCL. I've posted about them previously as has hweb. I've now taken over the RBCL board and have organized my DD. Here it is:
RBCL made $0.029/share last quarter (fully taxed) and last traded at $0.826. Last quarter they had a one time charge of $134,000. Without that charge they would have made $0.033/share. They have been growing revenue and have a backlog near record levels. I think next quarter RBCL will have an EPS in the $0.028-$0.04 range. I think there is a very good chance that RBCL will double in the next year to the $1.80/share range!
Board
http://investorshub.advfn.com/boards/board.asp?board_id=9877
Overview
RBC Life Sciences, Inc., together with its subsidiaries, engages in the marketing and distribution of nutritional supplements and personal care products in the United States, Canada, South Korea, and Japan. It operates in two segments, Nutritional Products and Medical Products. The Nutritional Products segment offers a line of approximately 75 nutritional supplements and personal care products, including herbs, vitamins, and minerals, as well as natural skin, hair, and body care products under the RBC Life Sciences brand. It markets these products in four categories: wellness products, weight loss products, fitness products, and skin care products. This segment markets its products through a network of independent distributors, as well as through licensing arrangements with third parties. The Medical Products segment markets a line of approximately 28 wound care and oncology products under the MPM Medical brand throughout the United States. The wound care products are for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions. These products include wound and skin cleansers, wound dressings, a moisture barrier cream, and hydrogel wound dressing with Lidocaine. The oncology products are designed to reduce destruction to skin and tissue caused by radiation, and to reduce pain and itching caused by radiation reactions in the skin and the internal mucosa. This segment distributes these products to hospitals, nursing homes, clinics, and pharmacies through medical/surgical supply dealers and pharmaceutical distributors.
Web Sites
http://www.rbclifesciences.com
http://www.mpmmedicalinc.com
Historical Financial Information
Note that there is seasonality in their numbers. Q2 and Q4 are the strongest quarters.
Earnings Reports
Q3'07 - http://investorshub.advfn.com/boards/read_msg.asp?message_id=25632255
Backlog Information
http://investorshub.advfn.com/boards/read_msg.asp?message_id=25632740
Charts
Mike
RBCL made $0.029/share last quarter (fully taxed) and last traded at $0.826. Last quarter they had a one time charge of $134,000. Without that charge they would have made $0.033/share. They have been growing revenue and have a backlog near record levels. I think next quarter RBCL will have an EPS in the $0.028-$0.04 range. I think there is a very good chance that RBCL will double in the next year to the $1.80/share range!
Board
http://investorshub.advfn.com/boards/board.asp?board_id=9877
Overview
RBC Life Sciences, Inc., together with its subsidiaries, engages in the marketing and distribution of nutritional supplements and personal care products in the United States, Canada, South Korea, and Japan. It operates in two segments, Nutritional Products and Medical Products. The Nutritional Products segment offers a line of approximately 75 nutritional supplements and personal care products, including herbs, vitamins, and minerals, as well as natural skin, hair, and body care products under the RBC Life Sciences brand. It markets these products in four categories: wellness products, weight loss products, fitness products, and skin care products. This segment markets its products through a network of independent distributors, as well as through licensing arrangements with third parties. The Medical Products segment markets a line of approximately 28 wound care and oncology products under the MPM Medical brand throughout the United States. The wound care products are for the treatment and healing of wounds, such as pressure ulcers, leg ulcers, cuts, burns, and abrasions. These products include wound and skin cleansers, wound dressings, a moisture barrier cream, and hydrogel wound dressing with Lidocaine. The oncology products are designed to reduce destruction to skin and tissue caused by radiation, and to reduce pain and itching caused by radiation reactions in the skin and the internal mucosa. This segment distributes these products to hospitals, nursing homes, clinics, and pharmacies through medical/surgical supply dealers and pharmaceutical distributors.
Web Sites
http://www.rbclifesciences.com
http://www.mpmmedicalinc.com
Historical Financial Information
Note that there is seasonality in their numbers. Q2 and Q4 are the strongest quarters.
Quarter Revenue Diluted EPS
Q3'07 $7.86M $0.029
Q2'07 $7.15M $0.023
Q1'07 $5.39M $0.015
Q4'06 $5.28M $0.005
Q3'06 $5.40M $0.004
Q2'06 $6.20M $0.013
Q1'06 $4.81M -$0.002
Q4'05 $4.95M $0.003
Q3'05 $4.91M $0.007
Q2'05 $5.36M $0.018
Q1'05 $4.14M $0.000 (very slight loss)
Q4'04 $5.24M $0.014
Q3'04 $4.07M $0.001
Q2'04 $4.72M $0.007
Q1'04 $4.24M $0.004
Earnings Reports
Q3'07 - http://investorshub.advfn.com/boards/read_msg.asp?message_id=25632255
Backlog Information
http://investorshub.advfn.com/boards/read_msg.asp?message_id=25632740
Charts
Mike
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
